AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OPTHEA LTD

0.600

+0.000

Volume:- -

Turnover:- -

Market Cap:738.77M

PE:-1.44

High:0.600

Open:0.600

Low:0.600

Close:0.600

Loading ...

Overview Company News Filings

Is Opthea Limited (OPT) One of the Best ASX Stocks to Buy According to Hedge Funds?

Why Opthea (OPT) Is Among the Best Australian Stocks to Buy Now?

Why this speculative ASX stock could rocket 70%

Top 3 Australian High Growth Tech Stocks to Watch

Simply Wall St.

The next big thing: 10 industries and 17 stocks poised to break out in 2025

Biotech smallcap Opthea eyes 5% jump as key drug of interest validated in paper

The Market Herald

Why Capricorn Metals, IDP Education, Life360, and Opthea shares are storming higher

Opthea Says Combination Therapy Candidate for Diabetes-Related Vision Loss Shows Potential in Phase 1B Study

MT Newswires Live

There's more to Australian biotech than just CSL: the opportunities to watch

High Growth Tech Stocks To Watch In Australia December 2024

Simply Wall St.

Opthea’s Wet AMD Program to be Featured at FLORetina 2024

Opthea Appoints Kathy Connell to Board of Directors

THOMSON REUTERS

Press Release: Opthea Appoints Kathy Connell to Board of Directors

Opthea Receives AU$15.9 Million Tax Incentive; Shares Down 6%

MT Newswires Live

High Growth Tech Stocks in Australia for November 2024

Simply Wall St.

Opthea’s Wet AMD Program Featured at Ophthalmology Events

Opthea Posts Lower Cash Balance in Quarter Ending Sept. 30

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OPT.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OPT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","market":"AU","secType":"STK","nameCN":"OPTHEA LTD","latestPrice":0.6,"timestamp":1744610400000,"preClose":0.6,"halted":3,"volume":0,"delay":0,"nameEN":"OPTHEA LTD","floatShares":786007538,"shares":1231287336,"eps":-0.41568016024213245,"marketStatus":"Halted","change":0,"latestTime":"04-14 16:00:00 AEST","open":0.6,"high":0.6,"low":0.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.41568016024213245,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1744675200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.6,"openAndCloseTimeList":[[1744588800000,1744610400000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","floatShares":786007538,"roa":"-73.34%","roe":"-3383.08%","lyrEps":-0.545141,"shares":1231287336,"dividePrice":0,"high":0.6,"amplitude":0,"preClose":0.6,"low":0.6,"week52Low":0.335,"pbRate":"-2.77","psRate":"2239.19","week52High":1.165,"institutionHeld":0,"latestPrice":0.6,"eps":-0.41568016024213245,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.41568016024213245,"open":0.6,"prevYearClose":0.81,"prevWeekClose":0.6,"prevMonthClose":0.6,"prevQuarterClose":0.6,"fiveDayClose":0.6,"twentyDayClose":0.6,"sixtyDayClose":0.82},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OPT.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2507190952","title":"Is Opthea Limited (OPT) One of the Best ASX Stocks to Buy According to Hedge Funds?","url":"https://stock-news.laohu8.com/highlight/detail?id=2507190952","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507190952?lang=en_us&edition=fundamental","pubTime":"2025-01-31 20:33","pubTimestamp":1738326811,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best ASX Stocks to Buy According to Hedge Funds.In this article, we are going to take a look at where Opthea Limited stands against other best ASX stocks to buy according to hedge funds.According to a report by the Australian Bureau of Statistics  published on December 4, 2024, the Australian economy grew by 0.3% in the September quarter of 2024, which marked the twelfth consecutive quarter of growth. This growth, however, was the lowest rate since the December quarter of 2020 after the COVID-19 pandemic. The report also noted that in nominal terms, GDP rose by 0.4%.In terms of trade, a key indicator of the economy’s international competitiveness fell by 2.5% in the quarter. This decline was primarily due to a 2.6% drop in export prices and was the third consecutive quarterly fall. The weakening in global bulk commodity demand, particularly from China, significantly affected the prices of metallurgical coal and iron ore. Import prices also fell sli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opthea-limited-opt-one-best-123331941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0267386448.USD","PSQ","QLD","SQQQ","LU0098860793.USD","LU0912757837.SGD","LU0158827948.USD","LU1989772840.SGD","LU2111349929.HKD","LU1548497426.USD","BK4534","LU1732799900.SGD","LU0225283273.USD","LU1989772923.USD","BK4581",".IXIC","BK4585","LU2089284900.SGD","USJW.SI","LU1162221912.USD","BK4588","NVIW.SI","BK4127","LU0320765646.SGD","IE00BKVL7J92.USD","LU0006306889.USD","LU2089283258.USD","QID","CKDXF","LU1732800096.USD","IE00BZ1G4Q59.USD","TSYW.SI","LU0795875086.SGD","LU0106831901.USD","BK4139","LU2028103732.USD","TQQQ","LU2271345857.HKD","USAW.SI","LU1363072403.SGD","MNQmain","LU2357305700.SGD","LU0314104364.USD","OPT","OPT.AU","LU0971096721.USD","BK4516","LU2023251221.USD","LU1074936037.SGD","NQmain"],"gpt_icon":1},{"id":"2506374776","title":"Why Opthea (OPT) Is Among the Best Australian Stocks to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2506374776","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506374776?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:04","pubTimestamp":1737983086,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Australian Stocks to Buy Now.In this article, we are going to take a look at where Opthea Limited  stands against other best Australian stocks to buy now.According to a report by Vanguard published on January 24, Australia’s economy is expected to experience a gradual recovery in 2025, following its slowest growth in 32 years in 2024. The report forecasts an economic growth of 2% year over year by the end of 2025, with trimmed mean inflation, a core measure that excludes items at the extremes, expected to reach 2.5% year over year. However, the report notes that low productivity growth and higher unit labor costs will keep core inflation from falling sustainably to the midpoint of the Reserve Bank of Australia’s  2%–3% target range until later in 2025.Why do we care about what hedge funds do?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-opthea-opt-among-best-130446898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU1989764664.SGD","LU0719512351.SGD","USAW.SI","AMD.AU","RBA","LU1242518857.USD","LU2098885051.SGD","LU1303367103.USD","IE00BMPRXN33.USD","BK4139","LU0823421333.USD","BK7067","USJW.SI","XKO.AU","XAO.AU","LU1064131342.USD","LU1923623000.USD","LU0109392836.USD","IE0009356076.USD","TSYW.SI","IE00BMPRXR70.SGD","MNQmain","BK4543","LU0757428866.USD","GFS","LU1815336091.USD","LU2250418816.HKD","IE00B5949003.HKD","LU0390134368.USD",".IXIC","OPT.AU","NQmain","BK4137","LU0823434583.USD","BK4141","NVIW.SI","LU0823421416.USD","BK7508","LU0081259029.USD","PSQ","XJO.AU","QID","QLD","TQQQ","BK4566","LU0082616367.USD","OPT","SQQQ"],"gpt_icon":1},{"id":"2503674082","title":"Why this speculative ASX stock could rocket 70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503674082","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503674082?lang=en_us&edition=fundamental","pubTime":"2025-01-16 04:15","pubTimestamp":1736972100,"startTime":"0","endTime":"0","summary":"Investors with a high tolerance for risk might want to take a look at the speculative ASX stock in this article. After all, the team at Bell Potter believes that it could deliver big returns for investors over the next 12 months if everything goes to plan. Which speculative ASX stock?The stock in question is Opthea Ltd . It is a biopharmaceutical company developing novel therapies that aim to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases. This includes wet age-related macular degeneration  and diabetic macular edema . Opthea's lead product candidate is sozinibercept. It is being evaluated in two fully enrolled pivotal Phase 3 clinical trials  for use in combination with standard-of-care anti-VEGF-A therapies. The trial aims to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone. What is the broker saying?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/16/why-this-speculative-asx-stock-could-rocket-70/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0127658192.USD","IE0009356076.USD","BK4585","LU0082616367.USD","LU1880398471.USD","LU0390134368.USD","LU0056508442.USD","LU0823421416.USD","BK4588","LU1989764664.SGD","BK4139","LU2360106780.USD","LU1803068979.SGD","LU1880398554.USD","LU1064131342.USD","LU1951198990.SGD","LU0109392836.USD","BK7067","LU2458330169.SGD","BK4532","IE0004445239.USD","LU2264538146.SGD","OPT","LU0823421333.USD","LU1316542783.SGD","BK4141","BK4575","LU1303367103.USD","BK7508","LU2054465674.USD","LU1242518931.SGD","LU2250418816.HKD","DME.AU","IE00B5949003.HKD","LU0823434583.USD","LU1242518857.USD","BK4543","LU1988902786.USD","BK4529","BK4512","LU0642271901.SGD","LU0823434740.USD","LU0889565833.HKD","OPT.AU","BK4573","LU0719512351.SGD","LU2458330243.SGD","LU1951200564.SGD","GFS"],"gpt_icon":1},{"id":"2502000987","title":"Top 3 Australian High Growth Tech Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2502000987","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502000987?lang=en_us&edition=fundamental","pubTime":"2025-01-10 12:03","pubTimestamp":1736481781,"startTime":"0","endTime":"0","summary":"The Australian market has recently experienced a downturn, with the ASX200 down 0.6% at 8,280 points amid concerns over upcoming US jobs data and broader global economic uncertainties. In this challenging environment where nearly all sectors are showing declines, identifying high-growth tech stocks can be crucial for investors seeking opportunities; these companies often demonstrate resilience and potential through innovation and strategic positioning despite broader market volatility.Nuix has recently transitioned into profitability, a notable achievement that aligns with its 40.2% forecasted annual earnings growth, outpacing the Australian market's average of 12.5%. Despite a revenue growth rate of 15.2%, which lags behind the high-growth tech sector's norm of over 20% annually, Nuix stands out for its positive free cash flow and commitment to innovation, as evidenced by significant R&D investments. This strategic focus on development could enhance its software solutions' competitive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-3-australian-high-growth-040301062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","OPT","NXL.AU","OPT.AU","XRO.AU"],"gpt_icon":0},{"id":"2502026684","title":"The next big thing: 10 industries and 17 stocks poised to break out in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502026684","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502026684?lang=en_us&edition=fundamental","pubTime":"2025-01-10 04:00","pubTimestamp":1736452814,"startTime":"0","endTime":"0","summary":"Move over big tech, there are more opportunities in town.After starting 2024 with earnings downgrades for a range of sectors and a slowdown in consumer spending, it was a bumper year for a number of sectors. Consumer discretionary was one surprise winner, with well-positioned brands like JB Hi-Fi and Nick Scali taking charge. Australian banks facing into a tougher environment continued to outperform, as did the financial sector on the whole, with insurers taking advantage of higher premiums. Biotech also started to surge, as falling rates outside of Australia and a number of successful clinical trials bolstered the sector.Of course, the big tech companies continued to dominate and push markets to record highs - it's hard to ignore the extraordinary growth in the likes of Nvidia for example, but it's worth noting the pace of the growth seems to be moderating somewhat.With valuations at a premium in the tech sector, there are a range of other areas where fund managers are hunting for big","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-next-big-thing-10-industries-and-17-stocks-poised-to-break-out-in-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-next-big-thing-10-industries-and-17-stocks-poised-to-break-out-in-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["AFG.AU","BK4585","ACL.AU","BK7016","IE0008368304.USD","XJO.AU","HLS.AU","LU2357125470.USD","LU0823414478.USD","BK7067","BK4533","BK7501","SHL.AU","LU0823414551.USD","ASB.AU","BK4504","BK4232","BOE.AU","LU2249611893.SGD","CSC.AU","BK4156","BK4566","XKO.AU","BK7160","BK7115","BK7124","BK7508","DSE.AU","AS","BK4591","LU2506951792.HKD","BK4022","BK7503","BK7083","BK4202","CCJ","BK7110","XAO.AU","GTK.AU","OPT.AU","ODFL","BK7123","BK7509","LU2294711713.HKD","BK4588"],"gpt_icon":0},{"id":"2501245417","title":"Biotech smallcap Opthea eyes 5% jump as key drug of interest validated in paper","url":"https://stock-news.laohu8.com/highlight/detail?id=2501245417","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501245417?lang=en_us&edition=fundamental","pubTime":"2025-01-07 11:09","pubTimestamp":1736219340,"startTime":"0","endTime":"0","summary":"Dual ASX and NASDAQ listed Opthea Ltd  has jumped 4.5% to 77cps today after having its diabetic eye drug of interest further validated as a potential treatment in a scientific paper.Treating Diabetic Macular Edema  – a condition associated with diabetes that is sight-threatening where blood vessels leak fluid – is among Opthea’s key goals, using the drug sozinibercept.According to a presentation on the company’s website , the drug represents a “multibillion-dollar” opportunity.The drug is a “first-in-class” protein-based compound that combines different naturally occurring proteins in specific combinations intended to target key areas of the body. In this case, the eye, where affected by DME.The reason shares were climbing on Tuesday was the drug appears to have been partially validated in a paper published in the peer-reviewed journal Translational Vision Science & Technology this week.The material provided in this article is for information only and should not be treated as investmen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/biotech-smallcap-opthea-eyes-5-jump-as-key-drug-of-interest-validated-in-paper-2025-01-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["IE0009356076.USD","OPT.AU","IE00BMPRXN33.USD","IE00B5949003.HKD","LU1880398471.USD","BK4588","LU0823421416.USD","LU0056508442.USD","BK4534","LU2250418816.HKD","LU0823434740.USD","BK4139","LU0823421333.USD","BK4573","IE00BMPRXR70.SGD","BK4566","LU1880398554.USD","LU1989764664.SGD","LU0823434583.USD","LU1988902786.USD","LU2098885051.SGD","LU0198837287.USD","LU2054465674.USD","OPT","LU1951198990.SGD","LU1852331112.SGD","BK7095","LU0642271901.SGD","GFS","LU1242518857.USD","BK4532","LU2360106780.USD","LU0390134368.USD","BK4554","DME.AU","LU0719512351.SGD","BK4529","BK4575","LU0109392836.USD","LU0082616367.USD","LU1242518931.SGD","BK7508","LU1303367103.USD","LU2458330243.SGD","LU0979878070.USD","BK4512","AMD","BK4141","LU1316542783.SGD","IE0004445239.USD"],"gpt_icon":1},{"id":"2501214510","title":"Why Capricorn Metals, IDP Education, Life360, and Opthea shares are storming higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2501214510","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501214510?lang=en_us&edition=fundamental","pubTime":"2025-01-07 10:23","pubTimestamp":1736216601,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is on course to record another small gain. In afternoon trade, the benchmark index is up 0.3% to 8,281.6 points. Four ASX shares that are rising more than most today are","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/07/why-capricorn-metals-idp-education-life360-and-opthea-shares-are-storming-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","IEL.AU","OPT","BK7067","OPT.AU","BK4023","BK7508","BK7095","BK7104","CMM.AU","LIF","360.AU","BK4139","DME.AU","BK7132","BK7016"],"gpt_icon":0},{"id":"2501290547","title":"Opthea Says Combination Therapy Candidate for Diabetes-Related Vision Loss Shows Potential in Phase 1B Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2501290547","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501290547?lang=en_us&edition=fundamental","pubTime":"2025-01-07 08:34","pubTimestamp":1736210084,"startTime":"0","endTime":"0","summary":"Opthea  said its combination therapy candidate for diabetic macular edema showed potential in a first-in-human phase 1b study, according to a Tuesday filing with the Australian bourse.The study tested the combination of sozinibercept and aflibercept in nine patients, with safety as the primary endpoint and mean change from baseline in best-corrected visual acuity as one of the secondary endpoints, the filing said.Based on the results, the therapy was well tolerated, with no dose-limiting toxicities, the filing said. In addition, the 2 mg sozinibercept combination arm showed the highest best-corrected visual acuity gain.Results from the study were published in the peer-reviewed journal Translational Vision Science & Technology, per the filing.The company's shares rose past 5% in recent Tuesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","OPT","BK7067","OPT.AU"],"gpt_icon":1},{"id":"2491503738","title":"There's more to Australian biotech than just CSL: the opportunities to watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2491503738","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491503738?lang=en_us&edition=fundamental","pubTime":"2024-12-16 04:09","pubTimestamp":1734293355,"startTime":"0","endTime":"0","summary":"Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren and Telix delivering FDA approved products and becoming profitable. Botanix has also recently received FDA approval and is set to launch shortly, further enhancing the sector’s credibility.Several other companies including Opthea , Immutep and Dimerix are progressing through Phase 3 trials, while Syntara is set to potentially begin a Phase 3 trial in 2025, pending feedback from the FDA. The local ecosystem is starting to mature and is looking better and better.There are two competing schools of thought within the incoming US administration that are diametrically opposed on what direction the FDA should take. However, what remains certain is the continued need for robust drug and device development.In contrast to the US, Australia’s, regulatory environment is much more stable. The federal government is highly supportive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["CVB.AU","LU1169589451.USD","DXB.AU","BK7502","BK7096","CSL","IMM.AU","SGXZ23171101.USD","LU0728928796.USD","BK4086","BK7007","XJO.AU","BK7067","SG9999004303.SGD","BK7511","BK7508","XKO.AU","SNT.AU","LU1169590202.USD","NEU.AU","CSL.AU","OPT.AU","BOT.AU","BK7501","TLX.AU","XAO.AU"],"gpt_icon":0},{"id":"2490825620","title":"High Growth Tech Stocks To Watch In Australia December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490825620","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490825620?lang=en_us&edition=fundamental","pubTime":"2024-12-12 12:02","pubTimestamp":1733976168,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a mixed landscape with the ASX200 slightly down by 0.2% and a tight labor market reflected in an unemployment rate of 3.9%, sectors like Information Technology are showing resilience with modest gains amidst broader economic challenges. In this environment, identifying high growth tech stocks involves looking for companies that can leverage innovation and adaptability to capitalize on emerging opportunities, particularly as certain sectors like Energy and Information Technology demonstrate potential despite overall market fluctuations.Overview: Opthea Limited is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs for eye diseases in Australia and the United States, with a market cap of A$824.83 million.Operations: Opthea Limited generates revenue primarily from its Medical Technology and Healthcare segment, amounting to $0.26 million. The company is focused on the development and commercialization of eye disease ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gnGTQ_q9KCdl7Xvx_ppB0g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0fe4d5d105492213ce106a92b49639d4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gnGTQ_q9KCdl7Xvx_ppB0g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0fe4d5d105492213ce106a92b49639d4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-040248655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OPT.AU","OPT","NXL.AU","BK4139","XRO.AU"],"gpt_icon":0},{"id":"2486794230","title":"Opthea’s Wet AMD Program to be Featured at FLORetina 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2486794230","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486794230?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:00","pubTimestamp":1732622400,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024  -- Opthea Limited , a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration , today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLORetina aims to provide cutting-edge insights on research and clinical development from world-leading experts in the field of medical retina, retinal surgery, and imaging.Retina Futura 1: Wet Age-Related Macular Degeneration : Emerging Therapies and Clinical Updates. Beyond VEGF-A Inhibition: Will Blocking VEGF-C and VEGF-D Lead to Better Outcomes?Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials  for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LZDMo8Ip.F91.f.20jln9Q--~B/aD00NDt3PTE4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5331240e244361fae836b1301337116a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LZDMo8Ip.F91.f.20jln9Q--~B/aD00NDt3PTE4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5331240e244361fae836b1301337116a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opthea-wet-amd-program-featured-120000914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1852331112.SGD","LU1923623000.USD","BK4534","BK4512","LU0719512351.SGD","LU2458330169.SGD","LU0127658192.USD","BK4566","LU0823421416.USD","LU0823434740.USD","LU0056508442.USD","LU1951200564.SGD","BK4585","BK4575","LU1064131342.USD","LU2360106780.USD","LU1880398471.USD","IE00BMPRXN33.USD","LU0823421333.USD","LU1989764664.SGD","IE0009356076.USD","LU2458330243.SGD","LU0979878070.USD","IE00BMPRXR70.SGD","LU1988902786.USD","IE00B5949003.HKD","BK4532","LU0082616367.USD","BK4573","BK4554","LU0081259029.USD","LU0823434583.USD","BK4139","LU1242518857.USD","OPT","LU1951198990.SGD","LU0109392836.USD","LU2264538146.SGD","LU1242518931.SGD","LU1303367103.USD","BK4529","LU2250418816.HKD","LU1316542783.SGD","BK4588","OPT.AU","GFS","LU0889565833.HKD","LU0642271901.SGD","AMD","LU1880398554.USD","LU0198837287.USD"],"gpt_icon":1},{"id":"2483242333","title":"Opthea Appoints Kathy Connell to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2483242333","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483242333?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:00","pubTimestamp":1731672048,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nTUA4GMPM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2483764324","title":"Press Release: Opthea Appoints Kathy Connell to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2483764324","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483764324?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:00","pubTimestamp":1731672000,"startTime":"0","endTime":"0","summary":"Ms. Connell is a commercial executive with business development expertise. Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025. Ms. Connell is a commercial executive with deep business development expertise across pharmaceutical, vaccine, medtech, consumer and digital health industries. Her track record of translating global commercial strategies into impactful business results and shareholder value will be instrumental as Opthea prepares for the topline data readout of its pivotal program of sozinibercept in wet AMD. Ms. Connell is currently Senior Client Partner and Head of Healthcare and Life Sciences Australia/New Zealand at Korn Ferry. She also serves as Non-Executive Director at Avecho Biotechnology Ltd , Proto Axiom  and BioNSW .\"On behalf of Opthea organization, I want to thank Dr. Baldwin for her many years of dedicated Board service and express my gratitude for her continued, active engagement as Opthea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","IE00BMPRXR70.SGD","BK4534","BK4575","BK4532","IE0004445239.USD","IE00BMPRXN33.USD","LU1803068979.SGD","GFS","LU0198837287.USD","OPT","LU0823434740.USD","LU1064131342.USD","BK4585","LU1303367103.USD","LU0642271901.SGD","LU2458330243.SGD","LU0109392836.USD","LU0823421416.USD","BK4141","BK4139","CIO","LU2360106780.USD","LU1880398471.USD","LU0979878070.USD","LU0719512351.SGD","BK4194","BK7508","LU2054465674.USD","OPT.AU","LU2264538146.SGD","LU2098885051.SGD","LU1988902786.USD","BK4529","LU1951198990.SGD","LU0127658192.USD","LU0056508442.USD","LU1242518857.USD","LU1923623000.USD","IE0009356076.USD","LU0823421333.USD","LU0889565833.HKD","LU1989764664.SGD","LU2250418816.HKD","LU1242518931.SGD","BK4588","LU1852331112.SGD","IE00B5949003.HKD"],"gpt_icon":1},{"id":"2483635039","title":"Opthea Receives AU$15.9 Million Tax Incentive; Shares Down 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483635039","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483635039?lang=en_us&edition=fundamental","pubTime":"2024-11-15 07:57","pubTimestamp":1731628640,"startTime":"0","endTime":"0","summary":"Opthea  received a AU$15.9 million research and development tax credit from the Australian Taxation Office, according to a Friday filing with the Australian bourse.The incentive is for research and development costs incurred in the financial years 2023 to 2024 relating to the development of Opthea's lead product candidate, sozinibercept, the filing stated.The biopharmaceutical company's shares were down 6% in recent Friday trade.Price : $0.66, Change: $-0.04, Percent Change: -5.71%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT.AU","LU0426417589.USD","BK7508","LU0994945656.USD","AUD","OPT","XAO.AU","LU0345774631.USD","LU1043141123.HKD","XKO.AU","BK4139","LU0426412945.USD","XJO.AU","BK4125","BK7067","LU2238339852.HKD"],"gpt_icon":0},{"id":"2483101020","title":"High Growth Tech Stocks in Australia for November 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483101020","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483101020?lang=en_us&edition=fundamental","pubTime":"2024-11-13 12:06","pubTimestamp":1731470812,"startTime":"0","endTime":"0","summary":"As the Australian market faces a slight downturn with the ASX200 down 1.1% and sectors like Financials and Health Care underperforming, investors are keeping a close eye on economic indicators such as the wage price index, which has shown modest growth. In this environment, identifying high-growth tech stocks becomes crucial as these companies often have the potential to outperform due to their innovative capabilities and adaptability in fluctuating market conditions.Click here to see the full list of 59 stocks from our ASX High Growth Tech and AI Stocks screener.Overview: Opthea Limited is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs for eye diseases in Australia and the United States, with a market cap of A$1.02 billion.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gnGTQ_q9KCdl7Xvx_ppB0g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0fe4d5d105492213ce106a92b49639d4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gnGTQ_q9KCdl7Xvx_ppB0g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0fe4d5d105492213ce106a92b49639d4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-australia-040652537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XAO.AU","BK4139","OPT","BK7503","BK7067","NXL.AU","BK7016","XKO.AU","XJO.AU","OPT.AU","XRO.AU","BK7508"],"gpt_icon":0},{"id":"2482708776","title":"Opthea’s Wet AMD Program Featured at Ophthalmology Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2482708776","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482708776?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:00","pubTimestamp":1731412800,"startTime":"0","endTime":"0","summary":"17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024. MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024  -- Opthea Limited , a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration , today announced that Opthea and sozinibercept will be highlighted during two upcoming Ophthalmology conferences.The 17th Congress of the Asia-Pacific Vitreo-Retina Society . Gregg T. Kokame, MD, MMM, FASRS, will present data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy , measured at 24 weeks. Data from this subgroup show that patients treated with a combination of sozinibercept and ranibizumab experienced significantly better visual and anatomic outcomes compared to ranibizumab alone.Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LZDMo8Ip.F91.f.20jln9Q--~B/aD00NDt3PTE4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5331240e244361fae836b1301337116a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LZDMo8Ip.F91.f.20jln9Q--~B/aD00NDt3PTE4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5331240e244361fae836b1301337116a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opthea-wet-amd-program-featured-120000994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0004445239.USD","LU0719512351.SGD","LU0823434740.USD","IE00BMPRXR70.SGD","LU2264538146.SGD","LU1242518857.USD","LU1064131342.USD","LU1242518931.SGD","LU1923623000.USD","LU0823421416.USD","LU1951200564.SGD","BK4139","LU1852331112.SGD","LU0109392836.USD","BK4512","OIS","LU1880398554.USD","BK4179","BK4554","LU1951198990.SGD","IE00B5949003.HKD","LU1316542783.SGD","LU2458330169.SGD","LU0082616367.USD","LU1303367103.USD","LU0127658192.USD","GFS","OPT","BK4141","LU2250418816.HKD","LU0823421333.USD","LU2458330243.SGD","BK4588","BK4585","LU0979878070.USD","LU2360106780.USD","BK4575","LU0823434583.USD","LU1988902786.USD","OPT.AU","LU1880398471.USD","LU2098885051.SGD","LU2054465674.USD","IE0009356076.USD","BK4532","LU0056508442.USD","LU1989764664.SGD","LU0081259029.USD","BK4573"],"gpt_icon":1},{"id":"2479139715","title":"Opthea Posts Lower Cash Balance in Quarter Ending Sept. 30","url":"https://stock-news.laohu8.com/highlight/detail?id=2479139715","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479139715?lang=en_us&edition=fundamental","pubTime":"2024-10-31 09:51","pubTimestamp":1730339462,"startTime":"0","endTime":"0","summary":"Biopharmaceutical company Opthea  said its cash balance fell to $167.5 million in the quarter ended Sept. 30 from $172.5 million in the quarter ended June 30, according to a Thursday filing with the Australian Securities Exchange.The company said the decrease was mainly due to the receipt of the retail entitlement finalized in July, which offset the operational spend of $39.8 million for two clinical trials.Cash receipts increased by 175% to $2.2 million, from $800,000 in the previous quarter, while net operating cash outflow increased to $41.2 million from the previous quarter's $38.6 million, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","OPT.AU","BK4139","OPT"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":77,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPT.AU\",market:\"AU\",,,undefined,":[]}}